Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 209610
Company: PADAGIS ISRAEL

Products on ANDA 209610

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE	BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE	3.75%;EQ 1.2% BASE	GEL;TOPICAL	Prescription	AB	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 209610

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
08/20/2024	ORIG-1	Approval		STANDARD	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/209610Orig1s000TA_ltr.pdf

Therapeutic Equivalents for ANDA 209610

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

GEL;TOPICAL; 3.75%;EQ 1.2% BASE
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE	BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE	3.75%;EQ 1.2% BASE	GEL;TOPICAL	Prescription	No	AB	209610	PADAGIS ISRAEL
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE	BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE	3.75%;EQ 1.2% BASE	GEL;TOPICAL	Prescription	No	AB	208683	SUN PHARMA CANADA
ONEXTON	BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE	3.75%;EQ 1.2% BASE	GEL;TOPICAL	Prescription	Yes	AB	050819	BAUSCH